Overview

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clarity Pharmaceuticals Ltd